礼来制药CEO戴维·里克斯独家接受CNBC-TV18采访，讲述该制药公司计划加大收购力度、消费者业务敞口扩大所带来的风险，以及突破性创新匮乏为何仍是其最大的长期担忧。
Eli Lilly CEO David Ricks speaks exclusively to CNBC-TV18 about the drugmaker’s plans to become more acquisitive, the risks from its growing consumer exposure and why a lack of breakthrough inventions remains its biggest long-term concern.
里克斯还讨论了礼来在印度的制造与技术布局、人工智能在药物研发中的作用，以及公司认为未来有望实现突破的治疗领域。
Ricks also discusses Lilly’s India manufacturing and technology ambitions, AI’s role in drug discovery and the therapeutic areas where the company sees potential for future breakthroughs.